TopFunds

Danaher Corp

NYSE: DHR

Stock price

227.81 USD

(-17.99%) 5 years

healthcareMedical - Diagnostics & Research

Financial Performance

Share

5Y price score: (26)

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: 266%

DATE RANGE:

%

ㅤ

  • Earnings per share

  • Free cash flow per share

  • Stock price

Time scale:

By default your notes are visible only to you.

160.9

52-week range

242.8

227.805

Your model inputs

Required return / cost of capital
%
FCFF terminal growth rate
%

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Valuation

Free Cash Flow Yield

Help
FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

3.5 %

Dividend Yield TTM

0.7 %

Market cap $

$ 160,144

Price / Earnings TTM

Help
P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

37.3

Price / Book TTM

3

PEG TTM

Help
Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

(7.9)

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

5 %

(16.2) %

266 %

Free cash flow per share growth

20.2 %

(1.8) %

59.4 %

Earnings per share growth

37.8 %

3.1 %

6.3 %

Founded: 1,984

Employees: 61,000

Business Summary:Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

Q&A

SEARCH
Get answers on financials, industry, fundamentals or other questions.

Contribute

By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more

VIEW ALL Q&A

Contribute or ask questions about business following TopFunds community guidelines

Fair Value Reference Estimate

Latest Earnings Call Takeaways

2026 Q3 (Oct 21, 2026)

1) Strategic Vision and Leadership Transition
- Julie Sawyer Montgomery has taken over as CEO, emphasizing the goal of becoming a leader in Life Sciences and Diagnostics.
- The company aims to accelerate sustainable core revenue growth and gain market share by enhancing commercial execution and leveraging the Danaher Business System (DBS).
- Four strategic priorities were outlined: commercial excellence, innovation, talent development, and disciplined capital allocation.
- The focus is on connecting capabilities across businesses to provide comprehensive solutions to customers, particularly in addressing complex challenges like Alzheimer's disease.

2) Financial Performance and Segment Results
- Q3 2026 results exceeded expectations, with sales of $6.6 billion and core revenue growth (excluding respiratory) of 5.5%, a 100 basis point improvement from Q2.
- Adjusted operating profit margin reached nearly 30%, reflecting strong operational execution.
- Core revenue growth by segment:
| Segment | Core Revenue Growth | |------------------|---------------------| | Biotechnology | 5% | | Life Sciences | 4.5% | | Diagnostics | 7% (excluding respiratory) | - Respiratory revenue was a headwind, contributing to a 3% overall core revenue growth.

3) Market Challenges and Headwinds
- Academic demand remains below historical levels, although there was a sequential improvement.
- Respiratory revenue faced a significant decline due to lower global infection rates, impacting overall growth.
- The company anticipates respiratory revenue to be a 150 basis point headwind in Q4, with a conservative estimate of $1.5 billion for the full year.

4) Operational and Product Initiatives
- Danaher is focusing on enhancing commercial execution by aligning teams around profitable growth and share gain metrics.
- The company is investing in AI and automation, exemplified by the launch of an AI-powered autonomous lab and partnerships with NVIDIA to accelerate AI adoption in scientific research.
- Recent acquisitions, including StatLab and Masimo, are expected to strengthen Danaher's capabilities and drive synergies across its platforms.

5) Guidance and Outlook
- For Q4 2026, core revenue growth (excluding respiratory) is projected to be in the 4%-5% range, with an adjusted operating profit margin of approximately 29.5%.
- Full-year adjusted diluted EPS guidance has been raised to $8.57-$8.62, indicating double-digit year-over-year growth.
- While the company expects core revenue growth to remain steady at 4%-5% for 2027, further details will be provided in January after Q4 results.

Bottom line: Danaher is positioned for sustainable growth with a strong focus on commercial execution and innovation under new leadership. The company’s strategic initiatives and operational improvements are expected to enhance shareholder value, despite current headwinds in specific segments.

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Danaher Corp — Financial Overview, Stock Price, Market Cap

Danaher Corp is a company. Founded in 1984. As of October 23, 2026, the company's market capitalization is $160143738031 with a current stock price of $227.81.